These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28849192)

  • 1. Chinese herb extract improves liver steatosis by promoting the expression of high molecular weight adiponectin in NAFLD rats.
    Liu X; Tong W; Zhao X; Zhang H; Tang Y; Deng X
    Mol Med Rep; 2017 Oct; 16(4):5580-5586. PubMed ID: 28849192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of Adiponectin Ameliorates Nonalcoholic Fatty Liver Disease via Inhibition of FoxO1 in Type I Diabetic Rats.
    Xie X; Yan D; Li H; Zhu Q; Li J; Fang YP; Cheung CW; Irwin MG; Xia Z; Lian Q
    J Diabetes Res; 2018; 2018():6254340. PubMed ID: 30186875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artemisia capillaris formula inhibits hepatic steatosis via an miR‑122‑induced decrease in fatty acid synthase expression in vivo and in vitro.
    Liu L; Zhao J; Li Y; Wan Y; Lin J; Shen A; Xu W; Li H; Zhang Y; Xu J; Peng J; Hong Z
    Mol Med Rep; 2016 Jun; 13(6):4751-8. PubMed ID: 27081834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway.
    Chen M; Xing J; Pan D; Peng X; Gao P
    Biomed Pharmacother; 2020 Aug; 128():110286. PubMed ID: 32521450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIRT1 mediates the role of RNA-binding protein QKI 5 in the synthesis of triglycerides in non-alcoholic fatty liver disease mice via the PPARα/FoxO1 signaling pathway.
    Zhang W; Sun Y; Liu W; Dong J; Chen J
    Int J Mol Med; 2019 Mar; 43(3):1271-1280. PubMed ID: 30664220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
    Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
    J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and significance of fat mass and obesity associated gene and forkhead transcription factor O1 in non-alcoholic fatty liver disease.
    Zhang J; Li S; Li J; Han C; Wang Z; Li C; Wang X; Liu Z; Wen J; Zheng L
    Chin Med J (Engl); 2014; 127(21):3771-6. PubMed ID: 25382334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis.
    Zhang L; Zhang Z; Li C; Zhu T; Gao J; Zhou H; Zheng Y; Chang Q; Wang M; Wu J; Ran L; Wu Y; Miao H; Zou X; Liang B
    Cell Mol Gastroenterol Hepatol; 2021; 11(3):697-724. PubMed ID: 33075563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation.
    Khaleel EF; Abdel-Aleem GA
    Arch Physiol Biochem; 2019 Feb; 125(1):64-78. PubMed ID: 29429367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
    Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
    Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimetazidine improves hepatic lipogenesis and steatosis in non‑alcoholic fatty liver disease via AMPK‑ChREBP pathway.
    Zhang Y; Li C; Li X; Wu C; Zhou H; Lu S; Liu X
    Mol Med Rep; 2020 Sep; 22(3):2174-2182. PubMed ID: 32705195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects and mechanisms of total alkaloids of Rubus alceaefolius Poir on non‑alcoholic fatty liver disease in rats.
    Zheng H; Zhao J; Zheng Y; Wu J; Liu Y; Peng J; Hong Z
    Mol Med Rep; 2014 Oct; 10(4):1758-64. PubMed ID: 25051256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a low-fat diet on the hepatic expression of adiponectin and its receptors in rats with NAFLD.
    Ma H; You GP; Cui F; Chen LF; Yang XJ; Chen LG; Lu HD; Zhang WQ
    Ann Hepatol; 2015; 14(1):108-17. PubMed ID: 25536648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Middle- and high-molecular weight adiponectin levels in relation to nonalcoholic fatty liver disease.
    Lian K; Feng YN; Li R; Liu HL; Han P; Zhou L; Li CX; Wang Q
    J Clin Lab Anal; 2020 Apr; 34(4):e23148. PubMed ID: 31880002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats.
    Zhang Y; Tang K; Deng Y; Chen R; Liang S; Xie H; He Y; Chen Y; Yang Q
    Biomed Pharmacother; 2018 Jun; 102():1025-1036. PubMed ID: 29710519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiponectin deficiency rescues high-fat diet-induced hepatic injury, apoptosis and autophagy loss despite persistent steatosis.
    Guo R; Nair S; Zhang Y; Ren J
    Int J Obes (Lond); 2017 Sep; 41(9):1403-1412. PubMed ID: 28559541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL).
    Chen G; Yu D; Nian X; Liu J; Koenig RJ; Xu B; Sheng L
    Sci Rep; 2016 Oct; 6():35531. PubMed ID: 27759039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Nonalcoholic Hepatic Steatosis by Shenling Baizhu Powder: Involvement of Adiponectin-Induced Inhibition of Hepatic SREBP-1c.
    Tang K; Deng Y; Zheng C; Nie H; Pan M; Chen R; Xie J; Yang Q; Zhang Y
    Oxid Med Cell Longev; 2020; 2020():9701285. PubMed ID: 33062150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanism of geniposide in improving free fatty acid metabolism in rats with non-alcoholic fatty liver disease].
    Liang HQ; Lin MT; Zhao X; Zhou HH; Wang HG; Li GH; Wang YJ; Zhang LM; Wang YY; Chen SD
    Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(3):470-475. PubMed ID: 28868866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.